Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-155 + paclitaxel
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABBV-155 + paclitaxel is a combination investigational therapy consisting of mirzotamab clezutoclax (ABBV-155), a first-in-class antibody-drug conjugate, and paclitaxel, a widely used chemotherapeutic agent. ABBV-155 is composed of a BCL-XL inhibitor payload, a solubilizing linker, and a monoclonal anti-B7H3 antibody, designed to target and induce apoptosis in B7H3-expressing tumor cells. Paclitaxel stabilizes microtubules, inhibiting mitosis and cell division. The combination is being studied primarily in adults with relapsed or refractory solid tumors, notably non-small cell lung cancer (NSCLC) and breast cancer.
- Other names
- mirzotamab clezutoclax + paclitaxel
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)B7-H3TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ABBV-155 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-155 + paclitaxel.